Patents by Inventor Sjoerd Nicolaas Wadman
Sjoerd Nicolaas Wadman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9234006Abstract: Provided are compounds, the use of the said compounds in treatment, for example treatment of microbial infections, particularly by Gram negative bacteria. The compounds are polymyxin-based and are represented by the formula (I): and pharmaceutically acceptable salts thereof, where X is —NHC(O)—, —C(O)—, —OC(O)—, —CH2— or —SO2—; R5 represents C0-12 alkyl(C4-6 heterocyclyl), or C2-12 alkyl or C0-12 alkyl(C3-8 cycloalkylyl). and the alkyl or cycloalkylyl bears one, two or three hydroxyl groups, or a —NR6R7 group, or one —NR6R7 group and one or two hydroxyl groups; and R1 to R4 and R6 to R8 are as defined in the description.Type: GrantFiled: November 16, 2012Date of Patent: January 12, 2016Assignees: Novacta Biosystems Limited, Cantab Anti-Infectives LimitedInventors: Mona Saadi, Esther Duperchy, Pamela Brown, Michael John Dawson, Sjoerd Nicolaas Wadman
-
Patent number: 9192569Abstract: A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection is described, the formulation being clear of visual particulates and comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol and optionally a buffer.Type: GrantFiled: August 9, 2011Date of Patent: November 24, 2015Assignee: Novacta Biosystems LimitedInventors: Antony Nicholas Appleyard, Sjoerd Nicolaas Wadman
-
Patent number: 9006392Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: GrantFiled: February 1, 2011Date of Patent: April 14, 2015Assignee: Novacta Biosystems LimitedInventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Publication number: 20150031602Abstract: Provided are compounds, the use of the said compounds in treatment, for example treatment of microbial infections, particularly by Gram negative bacteria. The compounds are polymyxin-based and are represented by the formula (I): and pharmaceutically acceptable salts thereof, where X is —NHC(O)—, —C(O)—, —OC(O)—, —CH2— or —SO2—; R5 represents C0-12 alkyl(C4-6 heterocyclyl), or C2-12 alkyl or C0-12 alkyl(C3-8 cycloalkyl). and the alkyl or cycloalkyl bears one, two or three hydroxyl groups, or a —NR6R7 group, or one —NR6R7 group and one or two hydroxyl groups; and R1 to R4 and R6 to R8 are as defined in the description.Type: ApplicationFiled: November 16, 2012Publication date: January 29, 2015Applicants: CANTAB ANTI-INFECTIVES LIMITED, NOVACTA BIOSYSTEMS LIMITEDInventors: Mona Saadi, Esther Duperchy, Pamela Brown, Michael John Dawson, Sjoerd Nicolaas Wadman
-
Patent number: 8741945Abstract: The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example Clostridium infection, such as C. perfringens, C. difficile, C. tetani, and/or C. botulinum, in particular C. difficile, especially infection of the colon and/or lower intestines and diarrhea associated with the microbial infection.Type: GrantFiled: May 21, 2012Date of Patent: June 3, 2014Assignee: Novacta Biosystems LimitedInventor: Sjoerd Nicolaas Wadman
-
Patent number: 8729031Abstract: Compounds of formula (IV) and pharmaceutical compositions comprising the same are described, wherein X1 and X2, R3, L, Ar1, p and Z have the values disclosed herein.Type: GrantFiled: February 2, 2010Date of Patent: May 20, 2014Assignee: Novacta Biosystems LimitedInventor: Sjoerd Nicolaas Wadman
-
Patent number: 8575094Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: November 5, 2013Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Publication number: 20130171252Abstract: Described is a pharmaceutical formulation of a capsule for oral delivery of a type B lantibiotic to the stomach comprising a hard gelatine, HPMC or starch capsule, and a type B lantibiotic of formula (I): wherein X is —NH(CH2)qNH2 and q is an integer 2 to 12.Type: ApplicationFiled: July 12, 2011Publication date: July 4, 2013Applicant: NOVACTA BIOSYSTEMS LIMITEDInventors: Antony Nicholas Appleyard, Sjoerd Nicolaas Wadman
-
Publication number: 20130137630Abstract: Described is a A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol such as glycerol and/or a saccharide and optionally a buffer, wherein said final formulation for infusion or direct injection is clear of visual particulates.Type: ApplicationFiled: August 9, 2011Publication date: May 30, 2013Applicant: NOVACTA BIOSYSTEMS LIMITEDInventors: Antony Nicholas Appleyard, Sjoerd Nicolaas Wadman
-
Patent number: 8329644Abstract: The present invention provides actagardine, actagradine B and deoxy actagardine B derivatives of formula (I), wherein: X1 denotes that the residue is Leu; Val; or Ile; X2 denotes that the residue is Leu; Val; or Ile; R1 represents an alkyl or heteroalkyl group, substituted by at least one hydroxyl substituent, and R2 represents hydrogen, or an alkyl or heteroalkyl group, optionally substituted by at least one hydroxyl substituent, or R1 and R2 taken together with the nitrogen atom represent a heterocyclic group having at least one hydroxyl substituent, wherein the heterocyclic group optionally further contains one or more heteroatoms; Z is an amino acid residue, —NR3R4, —NR5COR6, —NR5C(O)OR6; —NR5SOR6, NR5SO2R6; —NR5C(S)NR6R7, —NR5C(NR8)NR6R7, or —N?R9, where R3, R4, R5, R6, R7, R8 and R9 are independently hydrogen, or a group, optionally substituted, selected from alkyl, heteroalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl, with the proviso that R9 is not hydrogen; and Y is —S— or —S(O)—.Type: GrantFiled: July 18, 2008Date of Patent: December 11, 2012Assignee: Novacta Biosystems LimitedInventor: Sjoerd Nicolaas Wadman
-
Publication number: 20120309676Abstract: Described are certain salts of certain lantibiotic compounds, pharmaceutical compositions comprising the same and use of the salts and compositions for the treatment of microbial infection, particularly Methicillin-resistant Staphylococcus aureus (MRSA) infection. The salts have an aqueous solubility of 2.5 mg/mL or more.Type: ApplicationFiled: February 1, 2011Publication date: December 6, 2012Inventors: Sjoerd Nicolaas Wadman, Antony Nicholas Appleyard
-
Publication number: 20120302728Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: ApplicationFiled: February 1, 2011Publication date: November 29, 2012Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Publication number: 20120277145Abstract: The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example Clostridium infection, such as C. perfringens, C. difficile, C. tetani, and/or C. botulinum, in particular C. difficile, especially infection of the colon and/or lower intestines and diarrhoea associated with the microbial infection.Type: ApplicationFiled: May 21, 2012Publication date: November 1, 2012Inventor: Sjoerd Nicolaas Wadman
-
Patent number: 8283371Abstract: The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example Clostridium infection, such as C. perfringens, C. difficile, C. tetani, and/or C. botulinum, in particular C. difficile, especially infection of the colon and/or lower intestines and diarrhea associated with the microbial infection.Type: GrantFiled: January 12, 2010Date of Patent: October 9, 2012Assignee: Novacta Biosystems LimitedInventor: Sjoerd Nicolaas Wadman
-
Patent number: 8183202Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: May 22, 2012Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Patent number: 8183278Abstract: The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example Clostridium infection, such as C. perfringens, C. difficile, C. tetani, and/or C. botulinum, in particular C. difficile, especially infection of the colon and/or lower intestines and diarrhea associated with the microbial infection.Type: GrantFiled: January 12, 2010Date of Patent: May 22, 2012Assignee: Novacta Biosystems LimitedInventor: Sjoerd Nicolaas Wadman
-
Publication number: 20110294723Abstract: The present disclosure relates to compounds of formula (II): pharmaceutical compositions comprising same and use of the compounds and compositions for the treatment of microbial infection, particularly Methicillin-resistant Staphylococcus aureus (MRSA) infection.Type: ApplicationFiled: February 2, 2010Publication date: December 1, 2011Applicant: Novacta Biosystems LimitedInventor: Sjoerd Nicolaas Wadman
-
Publication number: 20100261638Abstract: The present invention provides actagardine, actagradine B and deoxy actagardine B derivatives of formula (I), wherein: X1 denotes that the residue is Leu; Val; or Ile; X2 denotes that the residue is Leu; Val; or Ile; R1 represents an alkyl or heteroalkyl group, substituted by at least one hydroxyl substituent, and R2 represents hydrogen, or an alkyl or heteroalkyl group, optionally substituted by at least one hydroxyl substituent, or R1 and R2 taken together with the nitrogen atom represent a heterocyclic group having at least one hydroxyl substituent, wherein the heterocyclic group optionally further contains one or more heteroatoms; Z is an amino acid residue, —NR3R4, —NR5COR6, —NR5C(O)OR6; —NR5SOR6, NR5SO2R6; —NR5C(S)NR6R7, —NR5C(NR8)NR6R7, or —N?R9, where R3, R4, R5, R6, R7, R8 and R9 are independently hydrogen, or a group, optionally substituted, selected from alkyl, heteroalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl, with the proviso that R9 is not hydrogen; and Y is —S— or —S(O)—.Type: ApplicationFiled: June 18, 2008Publication date: October 14, 2010Inventor: Sjoerd Nicolaas Wadman
-
Publication number: 20100179207Abstract: The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example Clostridium infection, such as C. perfringens, C. difficile, C. tetani, and/or C. botulinum, in particular C. difficile, especially infection of the colon and/or lower intestines and diarrhea associated with the microbial infection.Type: ApplicationFiled: January 12, 2010Publication date: July 15, 2010Applicant: NOVACTA BIOSYSTEMS LIMITEDInventor: Sjoerd Nicolaas Wadman
-
Publication number: 20090203583Abstract: The present invention provides methods for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject, the method comprising administering to the subject a type-B lantibiotic. In particular, the invention provides methods for the treatment or prophylaxis of a Clostridium difficile infection. The type-B lantibiotics may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: ApplicationFiled: January 21, 2009Publication date: August 13, 2009Applicant: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo